<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83959">
  <stage>Registered</stage>
  <submitdate>22/05/2009</submitdate>
  <approvaldate>12/06/2009</approvaldate>
  <actrnumber>ACTRN12609000444280</actrnumber>
  <trial_identification>
    <studytitle>The Paracetamol After traumatic Brain Injury Study</studytitle>
    <scientifictitle>A multi-centre phase 2b randomised controlled trial investigating the efficacy and safety of intravenous paracetamol in reducing core body temperature after traumatic brain injury</scientifictitle>
    <utrn />
    <trialacronym>The PARITY Study</trialacronym>
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Traumatic brain injury</healthcondition>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Other injuries and accidents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Dose: Intravenous paracetamol, 1 gram (100mls), administered over 30 minutes.

Schedule: Given every 4 hours for 3 days.</interventions>
    <comparator>Dose: Identical placebo: 100mls saline given intravenous over 30 minutes.

Schedule: every 4 hours for 3 days</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Bladder Temperature using temperature sensing indwelling catheters</outcome>
      <timepoint>Mean bladder temperature from the start of study treatment until 4 hours after completion of study treatment period (this is a 76 hour study period).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Blood Pressure (systolic and mean arterial pressure) measured by intra-arterial pressure monitor</outcome>
      <timepoint>6 hourly during study treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Liver function test</outcome>
      <timepoint>daily from first dose of study treatment to the 7th day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>serum Paracetamol levels (blood analysis) after a single dose of study drug and after final dose of study drug.</outcome>
      <timepoint>baseline, 30, 45, 90, 240 minutes after single dose.  240 minutes after final dose of study drug</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The use of Physical Cooling: defined as whether a physical cooling device (e.g. ice packs, cooling blanket or intravenous cooling catheter) was used - collected hourly (Yes/No)</outcome>
      <timepoint>Hourly from fisrt study drug treatment until 4 hours after final study drug treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Written informed consent has been obtained from the patients next of kin
Age &gt; 18 and &lt; 65
Non penetrating head injury requiring mechanical ventilation, and, with an abnormal CT head (defined by the presence of haemorrhage, contusion, swelling, compression of basal cisterns or herniation) 
Within 72 hours of injury
Presence (or imminent placement) of arterial cannula
Alanine transferase level &lt; 100</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Suspected paracetamol overdose
Clinician decision to institute any intervention that modifies body temperature 
Body temperature at time of recruitment less that 36 degrees celsius or greater than 38.9 degrees celcius 
Treatment with paracetamol, non-steroidal anti-inflammatory drugs or steroids in 3 days prior to admission 
History of chronic liver disease or chronic alcohol abuse 
Suspected malnutrition or weight &lt; 60 kg
Renal failure with serum creatinine &gt; 200 
Haemodynamic instability defined as systolic blood pressure &lt; 90 mmhg or requirement for noradrenaline or adrenaline exceeding 20mcg/minute 
Minor head injury: either normal CT head or not expected to be in intensive care for 72 hours
Suspected pregnancy
GCS&lt;3 with fixed dilated pupils 
Moribund patient expected to die within 24 hours 
Allergy to paracetamol
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealment was maintained by having independent pharmacy/nursing staff prepare study treatment using a shroud to mask the study treatment.</concealment>
    <sequence>Computer generated</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/09/2009</anticipatedstartdate>
    <actualstartdate>24/11/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate>30/12/2013</actualenddate>
    <samplesize>44</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2217</postcode>
    <postcode>4029</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>South Eastern Sydney and Illawarra Area Health Service</primarysponsorname>
    <primarysponsoraddress>Wollongong Hospital 
Loftus Street
Wollongong NSW 2500</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Australia and New Zealand College of Anaesthetists</fundingname>
      <fundingaddress>ANZCA House, 630 St Kilda Rd, Melbourne, Victoria 3004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>The Honda-St. George Critical Care Fellowship,
St. George and Sutherland Medical Research Foundation</fundingname>
      <fundingaddress>PO Box 35, Kogarah, NSW, 1485</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Although experimental and observational studies suggest that a raised body temperature after brain injury may be associated with adverse outcomes for patients, there is no evidence that intervening to reduce temperature improves patient outcomes.  Current clinical practice involves the variable use of strategies that modify temperature despite the clinical uncertainty.  The PARITY study is part of a programme of research developed at  St George Hospital and the George Institute for International Health aiming to provide rigorous, high quality research to assess the effect of interventions that target normothermia after traumatic brain injury on patient-centred outcomes.</summary>
    <trialwebsite>n/a</trialwebsite>
    <publication>n/a</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Nepean Lead Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>14/10/2009</ethicapprovaldate>
      <hrec>Nepean Lead HREC</hrec>
      <ethicsubmitdate>17/06/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Manoj K Saxena</name>
      <address>Deprtment of Intensive Care Medicine,
St George hospital, Gray street, kogarah, NSW 2217</address>
      <phone>+ 61 2 9113 3373</phone>
      <fax>+ 61 2 9113 3971</fax>
      <email>msaxena@george.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Manoj K Saxena</name>
      <address>Deprtment of Intensive Care Medicine,
St George hospital, Gray street, kogarah, NSW 2217</address>
      <phone>+ 61 2 9113 3373</phone>
      <fax>+ 61 2 9113 3971</fax>
      <email>msaxena@george.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Manoj K Saxena</name>
      <address>Deprtment of Intensive Care Medicine,
St George hospital, Gray street, kogarah, NSW 2217</address>
      <phone>+ 61 2 9113 3373</phone>
      <fax>+ 61 2 9113 3971</fax>
      <email>msaxena@george.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Manoj Saxena</name>
      <address>Department of Intensive Care Medicine, St. George Hospital,
Gray Street, Kogarah, NSW 2217</address>
      <phone>+61291133373</phone>
      <fax />
      <email>m.saxena@unsw.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>